FDA actions, label changes, off-label trial reads.
It started as an anecdote too common to ignore. People who went on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) to lose weight kept saying the same strange thing: they stopped wanting to drink.
Spironolactone is one of medicine’s great second acts. It was built in 1959 as a potassium-sparing diuretic and aldosterone antagonist — a blood-pressure and heart-failure drug — and it still does that job every day.
They are the two drugs that actually move the needle on male pattern baldness, and they work the same way — both throttle the enzyme that makes dihydrotestosterone, the hormone that shrinks scalp follicles.
They were designed to lower blood sugar by making you pee it out. Then the outcomes trials came back and rewrote cardiology and nephrology.
Bempedoic acid (brand name Nexletol, and the fixed-dose combination Nexlizet with ezetimibe) is the oral LDL-lowering drug built for the people statins fail — not because it works better, but because of where it works.
Evolocumab (Repatha), alirocumab (Praluent) and inclisiran (Leqvio) do something no statin can: they cut LDL cholesterol another 50 to 60 percent on top of a statin, often to numbers that were unreachable a decade ago.
No drug has travelled further on a longevity hypothesis than metformin. It is cheap, it has been prescribed for type 2 diabetes for decades, its mechanism touches the exact pathways — AMPK, mTOR, insulin signalling — that the science of aging keeps circling…
Naltrexone is a fully approved prescription drug — at 50 mg it blocks opioids to treat addiction. Take one-tenth of that dose and something strange happens: instead of blocking pain relief, a small body of research suggests it may quietly turn down the kind…
For two thousand years colchicine was a gout drug — a cheap, oral, plant-derived anti-inflammatory that doctors reached for when a big toe caught fire. Now it is the first pure anti-inflammatory the FDA has ever approved to reduce cardiovascular risk.
Cagrilintide is a long-acting amylin analog, and CagriSema staples it to semaglutide for a two-mechanism attack on obesity.
It was approved in the 1990s, it slows how fast you digest starch, and it is one of the most reliably replicated lifespan-extenders in the most rigorous animal aging program we have. That is the genuinely exciting part, and it is real.
Take a sliver of a GLP-1 drug — a fraction of the label dose — and you are supposed to get gentle fat loss, sharper metabolism, fewer side effects, even a longer life, all for less money. The pitch is everywhere this year.
A dozen-plus peptides got pushed off the legal compounding shelf, a gray market of unverified vials rushed in to fill the gap, and now the government is reversing course.
Programs funded by Bill Gates’s money are releasing tens of millions of mosquitoes a week, and the public revolt is loud.
At the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, researchers presented a retrospective TriNetX cohort comparing 10,225 stage I–III cancer patients who started a GLP-1 receptor agonist after diagnosis with 12,115 patients who star…
In February 2026, the United States Department of Health and Human Services (HHS) quietly walked back most of the FDA’s 2023 peptide restrictions — returning BPC-157, TB-500, CJC-1295, ipamorelin and ten others to legal compounding u…
In 2017, a JAMA team led by Ryan Van Wagoner bought 44 products sold online as selective androgen receptor modulators and put them through mass spec. Only 52 percent actually contained the SARM on the label.
Tirzepatide already has FDA approval for type 2 diabetes (Mounjaro) and obesity (Zepbound). Two large Phase 3 readouts in 2024 — SUMMIT in heart failure with preserved ejection fraction, and SURMOUNT-OSA in obstructive sleep apnea — produced results strong …
Tadalafil and sildenafil were born as cardiovascular drugs. Their original target was angina. The erection effect was a side-track that became the franchise.
On May 18, 2026, the FDA approved baxdrostat — brand name Baxfendy — as the first aldosterone synthase inhibitor ever cleared for hypertension. This is not another me-too pill.
Naltrexone was approved in 1984 at 50 mg for opioid addiction. At 1.5–4.5 mg — a dose that barely appears in the original pharmacology — it pulls a fundamentally different signal.
On February 21, 2025, the FDA declared the semaglutide shortage resolved. That single regulatory action changed who can compound what, under which authority, and for how long. The Outsourcing Facilities Association sued.
The standoff between conventional medicine and the peptide category isn’t an evidence dispute. It’s a training gap that compounds into a billing problem and a liability problem — but the training gap is the load- bearing wall.
A University of Pennsylvania NLP study analyzed 410,198 Reddit posts from 67,000 GLP-1 (glucagon-like peptide-1) receptor agonist users and surfaced menstrual irregularities and temperature dysregulation as recurring adverse signals — neithe…
GLP-1 receptor agonists (GLP-1 RAs) were built as diabetes drugs and discovered as weight drugs. The next discovery is already in motion: NIH-backed research confirms these molecules cross into the brain — not just modulate gut signals — and suppress the do…